8. Immunomodulators and antineoplastics

8.2. Antineoplastics and supportive medicines

### Cyclophosphamide

**Indication**
- Malignant neoplasms of breast
- **ICD11 code**: 2D2Z

**INN**
- Cyclophosphamide

**Medicine type**
- Chemical agent

**List type**
- Complementary

**Formulations**
- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Oral > Solid: 25 mg tablet; 50 mg tablet

**EML status history**
- First added in 1977 (TRS 615)
- Changed in 2015 (TRS 994)
- Changed in 2019 (TRS 1021)
- Changed in 2021

**Sex**
- All

**Age**
- Adolescents and adults

**Therapeutic alternatives**
- The recommendation is for this specific medicine

**Patent information**
- Patents have expired in most jurisdictions
  - Read more about patents.

**Tags**
- Cancer

**Wikipedia**
- Cyclophosphamide

**DrugBank**
- Cyclophosphamide

---

**Summary of evidence and Expert Committee recommendations**

The Expert Committee recommended the addition of new strength formulations of cyclophosphamide powder for injection (1 g and 2 g) to the EML.